Effect of PPARα activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes

European Journal of Pharmacology

Volumn 561, Issue 1-3, 2007, Pages 206-213

  Murakami, Kentaro ^a   Bujo, Hideaki ^a   Unoki, Hiroyuki ^a   Saito, Yasushi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipocyte; Fat tissue; IL 6; Macrophage; PPAR ; TNF

Indexed keywords

2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2,2 DICHLORO 12 (P CHLOROPHENYL) DODECANOIC ACID; 2,2-DICHLORO-12-(P-CHLOROPHENYL)-DODECANOIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAURIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FUNCTIONAL ASSESSMENT; IMMUNOMODULATION; INHIBITION KINETICS; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; MACROPHAGE; METABOLISM; SECRETION; WESTERN BLOTTING;

ADIPOCYTES; ANIMALS; BLOTTING, WESTERN; CELL LINE; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LAURIC ACIDS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; PPAR ALPHA; PPAR GAMMA; RNA, MESSENGER; RNA, SMALL INTERFERING; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947305119     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.12.037     Document Type: Article

References (33)

1. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., Digby J.E., Sewter C.P., Lazar M.A., Chatterjee V.K., and O'Rahilly S. Activators of peroxisome proliferators activated receptor gamma have depot specific effects on human preadipocyte differentiation. J. Clin. Invest. 100 (1997) 3149-3153
2. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., and Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13681-13686
3. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. PPARα negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054
4. Delerive P., Gervois P., Fruchart J.C., and Staels B. Induction of IkBα expression as a mechanism contributing to the anti-inflammatory activities of PPARα activators. J. Biol. Chem. 275 (2000) 36703-36707
5. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
6. Fernandez-Real J.M., Vayreda M., Richart C., Gutierrez C., Broch M., Vendrell J., and Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab. 86 (2001) 1154-1159
7. Ginsberg H.N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106 (2000) 453-458
8. Han Z., Boyle D.L., Chang L., Bennett B., Karin M., Yang L., Manning A.M., and Firestein G.S. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108 (2001) 73-81
9. Hayden J.M., and Reaven P.D. Cardiovascular disease in diabetes mellitus type 2: a potential role for novel cardiovascular risk factors. Curr. Opin. Lipidol. 11 (2000) 519-528
10. Hirose H., Kawai T., Yamamoto Y., Taniyama M., Tomita M., Matsubara K., Okazaki Y., Ishii T., Oguma Y., Takei I., and Saruta T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51 (2002) 314-317
11. Kitagawa Y., Bujo H., Takahashi K., Shibasaki M., Ishikawa K., Yagui K., Hashimoto N., Noda K., Nakamura T., Yano S., and Saito Y. Impaired glucose tolerance is accompanied by decreased insulin sensitivity in tissues of mice implanted with cells that overexpress resistin. Diabetologia 47 (2004) 1847-1853
12. Meyer K., Volkl A., Endele R., Kuhnle H.F., and Pill J. Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPARα). Arch. Toxicol. 73 (1999) 440-450
13. Miyazawa-Hoshimoto S., Takahashi K., Bujo H., Hashimoto N., Yagui K., and Saito Y. Roles of degree of fat deposition and its localization on VEGF expression in adipocyte. Am. J. Physiol., Endocrinol Metabol. 288 (2005) E1128-E1136
14. Miyazaki Y., Glass L., Triplitt C., Matsuda M., Cusi K., Mahankali A., Mahankali S., Mandarino L.J., and DeFronzo R.A. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44 (2001) 2210-2219
15. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., Klein S., and Coppack S.W. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82 (1997) 4196-4200
16. Mohamed-Ali V., Pinkney J.H., and Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. 22 (1998) 1145-1158
17. Pill J., and Kuhnle H.F. BM 17.0744: a structurally new antidiabetic compound with insulin-sensitizing and lipid-lowering activity. Metabolism 48 (1999) 34-40
18. Poynter M.E., and Daynes R.A. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signalling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273 (1998) 32833-32841
19. Report of a WHO Consultation, Definition, diagnosis and classification of diabetes mellitus and its complications, 1999. Part 1 Diagnosis and classification of diabetes mellitus. World Health Organization, Department of Noncommunicable Disease Surveillance, Geneva.
20. Reaven G.M. Pathophysiology of insulin resistance in human disease. Physiol. Rev. 75 (1995) 473-486
21. Rosen E.D., and Spiegelman B.M. PPAR: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (2001) 37731-37734
22. Rubin C.S., Lai E., and Rosen O.M. Acquisition of increased hormone sensitivity during in vitro adipocyte development. J. Biol. Chem. 252 (1977) 3554-3557
23. Sancéau J., Kaisho T., Hirano T., Wietzerbin J.J., and Kaisho T. Triggering of the human interleukin-6 gene by interferon-γ and tumor necrosis factor-α in monocytic cells involves cooperation between interferon regulatory factor-1, NFκB, and Sp1 transcription factors. J. Biol. Chem. 270 (1995) 27920-27931
24. Schafer S.A., Hansen B.C., Volkl A., Fahimi H.D., and Pill J. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)α activator, in non-human primates. Biochem. Pharmacol. 68 (2004) 239-251
25. Sheu M.Y., Fowler A.J., Kao J., Schmuth M., Schoonjans K., Auwerx J., Fluhr J.W., Man M.Q., Elias P.M., and Feingold K.R. Topical peroxisome proliferators activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J. Invest. Dermatol. 118 (2002) 94-101
26. Shibasaki M., Takahashi K., Itou T., Miyazawa S., Ito M., Kobayashi J., Bujo H., and Saito Y. Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha?. Diabetologia 45 (2002) 518-526
27. Straub R.H., Hense H.W., Andus T., Scholmerich J., Riegger G.A., and Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metab. 85 (2000) 1340-1344
28. Thieringer R., Fenyk-Melody J.E., Le Grand C.B., Shelton B.A.., Detmers P.A., Somers E.P., Carbin L., Moller D.E., Wright S.D., and Berger J. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J. Immunol. 164 (2000) 1046-1054
29. Tuyt L.M., Dokter W.H., Birkenkamp K., Koopmans S.B., Lummen C., Kruijer W., and Vellenga E. Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J. Immunol. 162 (1999) 4893-4902
30. Vozarova B., Weyer C., Hanson K., Tataranni P.A., Bogardus C., and Pratley R.E. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 9 (2001) 414-417
31. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
32. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112 (2003) 1785-1788
33. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., and Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity related insulin resistance. J. Clin. Invest. 112 (2003) 1821-1830